COLL News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

CO

Mkt Cap

$755.3M

Volume

405.55K

Next Earnings

November 5th

Loading chart

CO

COLLCollegium Pharmaceutical, Inc. Common Stock

COLL

Pay with—

Available Balance0.00

CO

Mkt Cap

$755.0M

Volume

405.55K

Next Earnings

November 5th

Chart Financials Earnings News About Insider Filings

Does Collegium Pharmaceutical (COLL) Have the Potential to Rally 111.39% as Wall Street Analysts Expect?Collegium Pharmaceutical (COLL) closed at $23.18 with a mean analyst price target of $49, suggesting 111.4% upside potential. The stock has a Zacks Rank #1 (Strong Buy) rating and shows positive earnings estimate revisions, with the consensus estimate for the current year increasing 3.8% over the last 30 days. However, the article cautions that price targets alone should not be the sole basis for investment decisions.Zacks Investment Research · Oct 16, 2026

New Strong Sell Stocks for October 7thZacks has added three stocks to its Strong Sell list today: Ardelyx (ARDX), a biopharmaceutical company with a 53.9% downward earnings revision; Southwest Airlines (LUV), a passenger airline with a 4.1% downward earnings revision; and Collegium Pharmaceutical (COLL), a specialty pharmaceutical company with a nearly 3% downward earnings revision over the last 60 days.Zacks Investment Research · Oct 7, 2026

Collegium Pharmaceutical Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Collegium Pharmaceutical announced the award of 50,305 restricted stock units (RSUs) to 34 newly hired non-executive employees on June 1, 2026, as material inducement for employment. The RSUs will vest over a three-year period with one-third vesting on June 10, 2027, followed by equal annual installments, subject to continued service.GlobeNewswire Inc. · Jun 5, 2026

Collegium to Participate in 2026 Jefferies Global Healthcare ConferenceCollegium Pharmaceutical announced its management will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference on June 3, 2026. The company, which specializes in CNS and pain management medications, recently completed the acquisition of AZSTARYS and reported Q1 2026 net revenues of $193.5 million, up 9% year-over-year, with JORNAY PM revenues up 36% year-over-year.GlobeNewswire Inc. · May 27, 2026

Collegium Completes Acquisition of AZSTARYS® from Corium TherapeuticsCollegium Pharmaceutical completed its acquisition of AZSTARYS, an ADHD treatment, from Corium Therapeutics for approximately $650 million. The acquisition is expected to be immediately accretive and includes patent protection through 2037. Collegium raised its 2026 financial guidance, projecting total product revenues of $865-$895 million and adjusted EBITDA of $475-$500 million, with expected annual synergies exceeding $50 million.Benzinga · May 12, 2026

Collegium's General Counsel Trims His Stake as the Company Doubles Down on ADHDCollegium Pharmaceutical's General Counsel David Dieter sold 6,224 shares (6.4% of his holdings) for $228,110 under a pre-planned trading arrangement. The sale is modest and non-discretionary, but the real story is Collegium's strategic pivot toward ADHD treatments, with Jornay PM growing 48% in its first full year and the company acquiring AZSTARYS for $650 million to accelerate its move away from pain management.The Motley Fool · Mar 31, 2026

Collegium to Present New Real-World Data at PainConnect 2026Collegium Pharmaceutical announced it will present two posters featuring real-world data from its pain medication portfolio at the American Academy of Pain Medicine's Annual Meeting in Salt Lake City (March 5-8, 2026). The presentations will highlight clinical insights on BELBUCA (buprenorphine buccal film) and its performance compared to other opioids, reflecting the company's focus on generating evidence for clinical practice.GlobeNewswire Inc. · Mar 5, 2026

Paris Hilton Shares Her Experience with JORNAY PM and Launches New 'Embrace Your Sparkle' Campaign with Collegium to Empower the ADHD CommunityCollegium Pharmaceutical announced a partnership with Paris Hilton to launch the 'Embrace Your Sparkle' campaign aimed at raising awareness about ADHD and reducing stigma. Paris Hilton shared her personal ADHD journey and her experience using JORNAY PM, an evening-dosed methylphenidate treatment designed to provide symptom support throughout the day. The campaign seeks to normalize conversations about ADHD management and encourage individuals to seek appropriate treatment.GlobeNewswire Inc. · Mar 3, 2026

Collegium Announces Poster Presentations at the 2025 National Association of Pediatric Nurse Practitioners National Conference on Pediatric Health CareCollegium Pharmaceutical, Inc. announced it will have two poster presentations highlighting real-world data from its ADHD treatment, Jornay PM, at the National Association of Pediatric Nurse Practitioners National Conference.GlobeNewswire Inc. · Mar 10, 2025

Collegium to Participate in Jefferies Global Healthcare ConferenceSTOUGHTON, Mass., May 29, 2024 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that management will participate in a fireside chat at the Jefferies Global Healthcare Conference being held in New York, NY from June 5-6, 2024.GlobeNewswire Inc. · May 29, 2024

to start trading

CO

COLLCollegium Pharmaceutical, Inc. Common Stock

COLL

Pay with—

Available Balance0.00

Your PositionYou don't own any COLL yet.

Related Tickers

Earnings